Philip Morris International (PMI) has entered into partnership with the Canada-based nicotine delivery start-up, Parallax, to develop a new nicotine-delivery product, the multinational said in a press note.

Founded by two pulmonary physicians, Parallax develops inhalable nicotine products and staff at the start-up are experts in product research, device design and pharmaceutical quality manufacturing, PMI said.
“The [partnership] agreement focuses on advancing the development and commercialisation of an effective nicotine-delivery system that leverages the most advanced technologies in pulmonary medicine,” PMI said, without specifying further details of the agreement.
Between them, Parallax co-founders Dr Noe Zamel and Dr Arthur Slutsky have published over 750 peer-reviewed papers and are leaders in the field of pulmonary research and medicine, PMI said.